Plus Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 20
- Market Cap
- -
- Introduction
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Plus Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT05460507
- Locations
- ๐บ๐ธ
The Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Plus Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT05034497
- Locations
- ๐บ๐ธ
Northwestern Memorial Hospital Olson Pavilion, Chicago, Illinois, United States
๐บ๐ธNorthshore University Hospital, Manhasset, New York, United States
๐บ๐ธLenox Hill Hospital, New York, New York, United States
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- Conditions
- Glioma
- Interventions
- Drug: Rhenium Liposome Treatment
- First Posted Date
- 2013-07-24
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Plus Therapeutics
- Target Recruit Count
- 55
- Registration Number
- NCT01906385
- Locations
- ๐บ๐ธ
Northshore University Hospital, Manhasset, New York, United States
๐บ๐ธUT Southwestern Medical Center, Dallas, Texas, United States
๐บ๐ธThe Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States